The global landscape of Alimentary Tract and Metabolism Medicine sales demonstrates notable market variations by country in 2024. Germany leads with $8.07 billion USD PPP, followed by South Korea at $7.23 billion, Japan at $5.4 billion, and Italy at $5.33 billion. The United Kingdom, Portugal, and Switzerland hold moderate positions with $3.16 billion, $1.55 billion, and $1.13 billion respectively. Less significant but growing markets include Australia, Chile, Slovakia, Finland, New Zealand, Estonia, and Luxembourg.
Year-on-year variations from 2023 highlight growth trajectories: New Zealand (16.07%), Portugal (11.47%), and Japan (8.37%) exhibit strong increases. In contrast, more mature markets like the United Kingdom (1.89%) and Chile (2.26%) show slower growth. The compound annual growth rate (CAGR) over the last five years underscores consistent yet moderate growth across these regions.
Future trends to watch include technological advancements in drug delivery, increasing prevalence of digestive and metabolic disorders, and expanding healthcare access in emerging markets. Strategic focus on innovation, affordability, and regional market dynamics will shape the trajectory of this sector.
Top countries in Alimentary Tract and Metabolism Medicine Sales by Country
| # | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 8,070 | 2023 | +3.07% | +4.45% | View data |
| 2 | 2 South Korea | 7,230 | 2023 | +5.8% | +6.89% | View data |
| 3 | 3 Japan | 5,400 | 2023 | +0.8% | +8.37% | View data |
| 4 | 4 Italy | 5,330 | 2023 | +0.96% | +5.05% | View data |
| 5 | 5 United Kingdom | 3,160 | 2023 | +2.04% | +1.89% | View data |
| 6 | 6 Portugal | 1,550 | 2023 | +13.72% | +11.47% | View data |
| 7 | 7 Switzerland | 1,130 | 2023 | +8.69% | +7.64% | View data |
| 8 | 8 Australia | 1,120 | 2023 | +1.57% | +3.2% | View data |
| 9 | 9 Chile | 1,120 | 2023 | -1.58% | +2.26% | View data |
| 10 | 10 Slovakia | 471.6 | 2023 | +2.77% | +4.72% | View data |
